<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529005</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0526</org_study_id>
    <nct_id>NCT04529005</nct_id>
  </id_info>
  <brief_title>Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients</brief_title>
  <official_title>Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>La Jolla Pharmaceutical Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard of catecholamine vasopressor management of perioperative hypotension in&#xD;
      kidney transplant patients carries significant risks and falls short in many ways. Currently,&#xD;
      there is an absence in the scientific literature and research describing the hemodynamic&#xD;
      effectiveness and safety of novel pharmacologic agents such as angiotensin II (Giapreza - Ang&#xD;
      II) in perioperative kidney transplant patients. Phase 3 registration trials have&#xD;
      demonstrated the superior safety and efficacy of Ang II (Giapreza) in distributive shock&#xD;
      patients compared to traditional vasopressor agents and the novel mechanism of action may&#xD;
      provide additional protection in renal transplant patients. The pilot study entails giving&#xD;
      informed and consenting kidney transplant recipients Ang II (Giapreza) as their first&#xD;
      vasopressor if the need for vasopressors emerge either intraoperatively or postoperatively in&#xD;
      kidney transplant recipients. The primary objective is to evaluate the safety and hemodynamic&#xD;
      effects of Ang II (Giapreza) in the renal transplant population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2020</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure - Intraoperative</measure>
    <time_frame>From date and time of study drug initiation during transplant operation until goal BP is attained (per ordering surgeon) to a maximum of 8 hours</time_frame>
    <description>Intraoperative - time to attainment of goal BP after starting AT2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure - Postoperative</measure>
    <time_frame>From date and time of study drug initiation after transplant operation until goal BP is attained (per ordering surgeon) up to a maximum of 24 hours</time_frame>
    <description>Postoperative - time to attainment of goal BP after starting AT2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arrhythmias</measure>
    <time_frame>From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.</time_frame>
    <description>Confirmed via EKG, flowsheet, or note documentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral/visceral ischemia</measure>
    <time_frame>From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.</time_frame>
    <description>Digital or other peripheral/visceral ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis</measure>
    <time_frame>From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.</time_frame>
    <description>Incidence of venous or arterial thrombosis occurring during the hospitalization for kidney transplant (captured by ultrasound or other diagnostic imaging)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fungal Infections</measure>
    <time_frame>From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.</time_frame>
    <description>Incidence of post-operative fungal infections prior to discharge (as documented by the clinical care team)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.</time_frame>
    <description>Incidence of hyperglycemia requiring use of an insulin infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acidemia</measure>
    <time_frame>From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.</time_frame>
    <description>Incidence of pH &lt; 7.2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor outcomes</measure>
    <time_frame>Intraoperatively and 72 hour postoperatively</time_frame>
    <description>Incidence of the need for additional vasopressor agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine - 1st post-op</measure>
    <time_frame>First SCr after the end of transplant surgery up to 24 hours after surgery is completed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine - 7 days post-op</measure>
    <time_frame>SCr at postop day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine - discharge</measure>
    <time_frame>SCr at discharge up to a maximum of 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Shock, Surgical</condition>
  <condition>Shock</condition>
  <condition>Hypotension and Shock</condition>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Intraoperative Hypotension</condition>
  <condition>Postoperative Hypotension</condition>
  <arm_group>
    <arm_group_label>Angiotensin II (Giapreza)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin II</intervention_name>
    <description>If intraoperative or postoperative hypotension occurs (e.g. SBP &lt; 120 mmHg) and the attending surgeon and/or attending anesthesiologist deems vasopressor therapy to be necessary, angiotensin II (Giapreza) will be the first vasopressor used for management.</description>
    <arm_group_label>Angiotensin II (Giapreza)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients &gt; 18 years of age&#xD;
&#xD;
          -  Receiving deceased donor kidney transplant&#xD;
&#xD;
          -  Pre-transplant Ejection Fraction (within past 18 months) &gt; 50%&#xD;
&#xD;
          -  Intraoperative or postoperative distributive shock (according to hospital and study&#xD;
             protocol) requiring vasopressor support&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant patients (they would be excluded from receiving a transplant)&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  History of mesenteric ischemia&#xD;
&#xD;
          -  History of aortic dissection&#xD;
&#xD;
          -  History of abdominal aortic aneurysm&#xD;
&#xD;
          -  Allergy to mannitol&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 1000 cell/mm3 (within past 18 months)&#xD;
&#xD;
          -  Diagnosis of Raynaud's phenomenon, systemic sclerosis or vasospastic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott T Benken, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois Hospital and Health Sciences System</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aulakh NK, Garg K, Bose A, Aulakh BS, Chahal HS, Aulakh GS. Influence of hemodynamics and intra-operative hydration on biochemical outcome of renal transplant recipients. J Anaesthesiol Clin Pharmacol. 2015 Apr-Jun;31(2):174-9. doi: 10.4103/0970-9185.155144.</citation>
    <PMID>25948896</PMID>
  </reference>
  <reference>
    <citation>Busse LW, Ostermann M. Vasopressor Therapy and Blood Pressure Management in the Setting of Acute Kidney Injury. Semin Nephrol. 2019 Sep;39(5):462-472. doi: 10.1016/j.semnephrol.2019.06.006. Review.</citation>
    <PMID>31514910</PMID>
  </reference>
  <reference>
    <citation>Campos L, Parada B, Furriel F, Castelo D, Moreira P, Mota A. Do intraoperative hemodynamic factors of the recipient influence renal graft function? Transplant Proc. 2012 Jul-Aug;44(6):1800-3. doi: 10.1016/j.transproceed.2012.05.042.</citation>
    <PMID>22841277</PMID>
  </reference>
  <reference>
    <citation>Day KM, Beckman RM, Machan JT, Morrissey PE. Efficacy and safety of phenylephrine in the management of low systolic blood pressure after renal transplantation. J Am Coll Surg. 2014 Jun;218(6):1207-13. doi: 10.1016/j.jamcollsurg.2014.01.058. Epub 2014 Mar 12.</citation>
    <PMID>24768292</PMID>
  </reference>
  <reference>
    <citation>Choi JM, Jo JY, Baik JW, Kim S, Kim CS, Jeong SM. Risk factors and outcomes associated with a higher use of inotropes in kidney transplant recipients. Medicine (Baltimore). 2017 Jan;96(1):e5820. doi: 10.1097/MD.0000000000005820.</citation>
    <PMID>28072739</PMID>
  </reference>
  <reference>
    <citation>Ciapetti M, di Valvasone S, di Filippo A, Cecchi A, Bonizzoli M, Peris A. Low-dose dopamine in kidney transplantation. Transplant Proc. 2009 Dec;41(10):4165-8. doi: 10.1016/j.transproceed.2009.08.058.</citation>
    <PMID>20005360</PMID>
  </reference>
  <reference>
    <citation>Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hästbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21.</citation>
    <PMID>28528561</PMID>
  </reference>
  <reference>
    <citation>Lankadeva YR, Kosaka J, Evans RG, Bellomo R, May CN. Urinary Oxygenation as a Surrogate Measure of Medullary Oxygenation During Angiotensin II Therapy in Septic Acute Kidney Injury. Crit Care Med. 2018 Jan;46(1):e41-e48. doi: 10.1097/CCM.0000000000002797.</citation>
    <PMID>29077618</PMID>
  </reference>
  <reference>
    <citation>Robert R, Guilhot J, Pinsard M, Longeard PL, Jacob JP, Gissot V, Hauet T, Seguin F. A pair analysis of the delayed graft function in kidney recipient: the critical role of the donor. J Crit Care. 2010 Dec;25(4):582-90. doi: 10.1016/j.jcrc.2010.02.011. Epub 2010 Apr 8.</citation>
    <PMID>20381298</PMID>
  </reference>
  <reference>
    <citation>Tóth M, Réti V, Gondos T. Effect of recipients' peri-operative parameters on the outcome of kidney transplantation. Clin Transplant. 1998 Dec;12(6):511-7.</citation>
    <PMID>9850443</PMID>
  </reference>
  <reference>
    <citation>Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, Kashani K, Szerlip HM, Prowle JR, Bihorac A, Finkel KW, Zarbock A, Forni LG, Lynch SJ, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Bellomo R; Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med. 2018 Jun;46(6):949-957. doi: 10.1097/CCM.0000000000003092. Erratum in: Crit Care Med. 2018 Aug;46(8):e824.</citation>
    <PMID>29509568</PMID>
  </reference>
  <reference>
    <citation>Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013 Sep;119(3):507-15. doi: 10.1097/ALN.0b013e3182a10e26.</citation>
    <PMID>23835589</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Scott Benken</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Giapreza</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

